Faculty Collaboration Database

Lacosamide in Lennox-Gastaut syndrome: case report. Clin Neuropharmacol 2012;35(3):148-9

Date

05/18/2012

Pubmed ID

22592511

DOI

10.1097/WNF.0b013e318255b649

Scopus ID

2-s2.0-84861487827 (requires institutional sign-in at Scopus site)   16 Citations

Abstract

INTRODUCTION: Lennox Gastaut syndrome (LGS) is an epileptic encephalopathy characterized by tonic, atonic, and atypical absence seizures usually refractory to pharmacological treatment. Patients generally continue with seizures despite treatment with the commercially available antiepileptic drugs (AEDs). Lacosamide (LCM) is a new AED recently approved for treatment of partial onset seizures with or without secondary generalization. Lacosamide has a novel mechanism of action that seems to be different in relation to other conventional AEDs.

OBJECTIVE: To report LCM-caused worsening of tonic seizures and electroencephalographic pattern in a patient with Lennox-Gastaut syndrome.

CASE REPORT: We report the evolution of a patient with LGS resistant to several AEDs with a cryptogenic hepatopathy in whom LCM caused worsening of tonic seizures and electroencephalographic pattern. Once LCM was discontinued, the patient returned to his clinical and electrical baseline.

CONCLUSION: Lennox Gastaut syndrome may exacerbate tonic seizures and electrical pattern of patients with LGS.

Author List

Andrade-Machado R, Benjumea-Cuartas V, Jaramillo-Jimenez E

Author

Rene Andrade-Machado MD, PhD Assistant Professor in the Neurology department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Acetamides
Electroencephalography
Humans
Intellectual Disability
Lennox Gastaut Syndrome
Male
Spasms, Infantile
Young Adult